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Poster Session I S259specific TCRs in recipient effector cells is an attractive new treat-
ment modality for patients after allogeneic stem cell transplantation
who are at high risk of infection. Themajority of CD8+T cells express
the conventional CD8ab heterodimer at the cell surface, while a subset
of CD8+ T cells express the CD8aa homodimer. CD8aa and CD8ab
interact both with MHC-I molecule. CD8aa acts as a co-receptor, al-
though with less efficiency as compared to CD8ab. Preferential ex-
pression of CD8aa may represent a mechanism modulating the
avidity of CD8+ T cells. CD8aa+ T cells display an effector memory
and terminally differentiated phenotype and are believed to derive
from CD8ab+ T cells that have down-regulated CD8b chain expres-
sion. We have identified CD8aa+ T cells in the peripheral blood cir-
culation in human healthy donors and in non-human primates (5%
and 16% respectively of CD8+ T cells) and defined their differentia-
tion status based on CD45RA, CCR7, CD27, and CD28 expression.
We showed for the first time that patients with melanoma, who re-
sponded successfully to peptide-based vaccination, showed Melan-A/
MART-1-specific T cells in the CD8aa+ T cell compartment. In
one patient (with stage IV melanoma and experienced full remission
after immunological therapy) Melan-A/MART-1-specific CD8aa+
T cells were detected up to five years after vaccination. This provides
support that CD8aa+ T cells may be instrumental in mediating clin-
ically relevant, long-lived, anti-tumor immune responses. The impact
of CD8aa and CD8ab expression in modulating T cell avidity as well
as the specific T cell signaling associated with transgenic TCRs is be-
ing evaluated in an in vitro model (insect cells and Jurkat T cells) by
assessing effector functions (e.g. proliferation, cytokine production),
and signaling cascades. We hypothesize that CD8aa+ T cells repre-
sent a novel compartment of long-lived memory T cells endowed
with CD8-independent high affinity TCRs. Such high avidity
TCRs, recognizing viral targets (i.e. CMV, EBV), are present in the
CD8aa+ T cell compartment and represent viable targets for passive
immune-therapy of infections after transplantation.149
TARGETING MYELOMA STEM CELLS WITH T CELLS ARMED WITH ANTI-
CD3 X ANTI-CD20 BISPECIFIC ANTIBODY (CD20BI) PRIOR TO ASCT
LEADS TO DEVELOPMENT OF ANTI-MYELOMA IMMUNE RESPONSES
POST AUTOLOGOUS STEM CELL TRANSPLANT THAT CAN BE BOOSTED
WITH TARGETED T CELLS
Lawrence, L.G., Archana, T., Muneer, A., Zaid, A.-K., Voravit, R.,
Jeffrey, Z., Lois, A., Elyse, P.N., Dana, S., Patricia, S.A., Karen, M.,
Joseph, U.P. Karmanos Cancer Institute, Wayne State University, De-
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Despite autologous stem cell transplant (ASCT), relapse is inevi-
table for patients withmultiplemyeloma (MM).MM is thought to be
derived from MM cancer stem cells (MMCSC) that express CD20
providing a unique target for activated T cells (ATC) armed with
anti-CD3 x anti-CD20 bispecific antibody (CD20Bi) that binds to
T cells and to CD20 on MMSCS. CD20Bi armed ATC can kill rit-
uximab-resistant CD20+ lymphoma cells (Exp Hemat 33:452). We
tested whether targeting CD20 onMMCSC prior to ASCTwould in-
duce anti-MMCSC immunity that could be transferred in the stem cell
product during ASCT. A phase Ib clinical trial was performed to de-
termine safety, and the development of anti-myeloma immunity before
and after ASCT in 12 patients (pts). Pts were given 2 infusions of 1010
aATC 1 week apart (immunotherapy 5 IT) after myeloma induction
therapy prior to ASCT.Twelve patients were consented and evaluable
for safety, blood and bone marrow phenotyping, cytotoxicity, and
IFNg Elispot before IT, after IT, and after ASCT. Twelve patients
are surviving between 190 and 615 days after ASCT. There were no
dose-limiting toxicities or delays in engraftment. IFNg EliSpots in-
creased in 5 out 12 pts directed at Daudi, 6 out of 12 at K562, and 5
out of 12 at RPMI 8226 after IT in patients compared to before IT.
Increased IFNgEliSpotswere also detected inPBMC from5of 12 pa-
tients directed atRPMI 8226 after ASCT. PBMC from5of 12patients
had detectable anti-RPMI 8226 responses after ASCTwithout a boost
and 3 of 3 patients that were boosted with a single infusion of CD20Bi
armed ATC at 6.5, 10.5, and 15.2 months after ASCT showed in-
creased anti-RPMI 8226 IFNg EliSpot responses from 200 to 610,
75 to 190, and 100 to 200 EliSpots per 106 PBL plated. These data
strongly suggest that targeting MMSCS with CD20Bi armed ATCcan induce immunity that can be detected after ASCT and this immu-
nity can be boosted by an additional single infusion of armed ATC be-
yond 6months after ASCT. Immune studies suggest that targeting can
immunize the patient’s immune system against antigens on MMCSC
and the process of ASCT can transfer this immunity and the immunity
can be boosted.150
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Background: Relapse remains the primary cause of failure of al-
loHSCT for hematologic malignancies, and treatment, including
DLI, is often incompletely effective. Cancer vaccines have the poten-
tial to enhance the graft-vs-leukemia effect associated with DLI.
This pilot trial utilizes a novel allogeneic donor-derived DC vaccine
that targets WT1, a tumor-associated antigen commonly expressed
in hematologic malignancies. The objectives are to assess safety, tox-
icity, feasibility, immune responses, and clinical activity of WT1-
peptide loaded DCs and DLI for children and adults with relapsed
hematologic malignancies after alloHSCT.
Design: Patients with hematologic malignancies that are WT1+
(immunohistochemistry or quantitative RT-PCR) and have relapsed
after alloHSCT are eligible. Donors (related, unrelated) and patients
must be HLA-A2+. Donor peripheral blood monocyte-derived DCs
are loaded with a combination of 3 HLA-A2 bindingWT1 peptides
linked to the 11-merHIVTAT peptide designed to enhance antigen
presentation. Treatment consists of vaccines (10 x 106 DCs subcuta-
neous and 2 x 106 DCs intradermal) every 2 weeks for 6 doses and
DLI (1 x 106 CD3+ T-cells/kg) every 4 weeks for 3 doses.
Results: 4 patients, 11-18 years of age have been treated; 3 with
acute lymphoblastic leukemia (ALL) and one with Hodgkin lym-
phoma. Donors were matched siblings in 3 cases and a 10/10 HLA
matched father in one case. Vaccines were successfully produced
from all donors. Vaccine and DLI administrations were well toler-
ated. The most common adverse events were mild, reversible pain
and pruritus at sites of vaccine and delayed type hypersensitivity
(DTH) skin test administration. One patient developed Grade I
skin GVHD that did not require treatment. 3 of 4 (75%) patients
had positive ELISPOT responses toWT1 peptides. DTH responses
to WT1 were seen in 2 of 4 (50%) and to the keyhole limpet hemo-
cyanin (KLH) control in 3 of 4 (75%). Immune responses were ob-
served in all 3 patients with ALL. Median overall survival was 12
months. 1 patient with ALL achieved complete remission without
evidence for disease by flow cytometry. 3 patients have died of dis-
ease.
Conclusions:This novel allogeneic immunotherapy regimen is fea-
sible, well tolerated, and associated with immune responses. This ap-
proach has the potential to augment the efficacy of DLI in the
management of post-transplant relapse of hematologic malignan-
cies. Accrual is ongoing.
Table. Patient Characteristics and Immune Responses
Time from Time fromDiagnosisAge
(years)/
SexTransplant/
Donor Typetransplant
to relapse
(months)Relapse
to vaccine
(months)WT1
ELISpotWT1
DTHKLH
DTHALL 18/F NMA/MSD 8 14 + + +Hodgkin’s 18/M NMA/MSD 1 32 - - -ALL 15/M MA/MSD 12 14 + - +ALL 11/M MA/MRD 11 29 + + +
S260 Poster Session ICR: Complete remission; DOD: Died of disease; MA: Myeloablative;
NMA: Non-myeloablative; MSD: matched sibling donor; MRD: matched
related donor.151
OUTCOMES AFTER CD34+ SELECTION WITH OR WITHOUT THE ADDI-
TION OF PHOTO-ALLODEPLETED T LYMPHOCYTES IN MYELOABLATIVE
HLA-MATCHED SIBLING TRANSPLANTATION
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Introduction: Photodepletion (PD) is a method to selectively de-
plete alloreactive lymphocytes from the graft to reduce graft versus
host disease (GVHD) in allogeneic stem cell transplantation. We
have previously reported results with PD and shown a low rate of re-
lapse without significant GVHD (Mielke, et al. and McIver, et al.
BBMT2011). In this retrospective analysis, we compared transplants
using photodepleted donor lymphocytes (n 5 24) with a similar co-
hort of T cell depleted (TCD) transplants (n 5 48).
Methods: All subjects received myeloablative conditioning with cy-
clophosphamide (120 mg/kg), fludarabine (125mg/m 2) and TBI (12
Gy, or 4 Gy for age $55). Peripheral blood stem cells were CD34+
selected by the Miltenyi CliniMacs system, with infusion of a target
CD34+ dose of 6 x 106/kg (range 3-10 x 106/kg) and a CD3+ dose of
\5 x 104 /kg. All patients received cyclosporine as the only GVHD
prophylaxis. The PD cohort received 5 x106/kg PD donor lympho-
cytes at day 0 while the TCD cohort received an unmanipulatedDLI
of 5 x106 CD3+/kg on day 90.
Results: Seventy-two patients underwent HLA-identical sibling
transplant. The median age was 43 years (range 16-68), 50% were
males. Transplant indications were AML (29), ALL (17), bipheno-
typic acute leukemia (2), MDS/MPD (15), CML (3), NHL/CLL
(6). Baseline characteristics were similar apart from a greater propor-
tion of high risk patients in the PD cohort (66% vs 50%).
The time to ANC .0.5 x 109/L and the time to complete donor
myeloid chimerism (median, day 14) were similar in both groups,
but PD transplants achieved earlier complete donor T-lymphocyte
engraftment (31 vs 45 days, p 5 0.01). Primary engraftment failure
was seen in 3 patients receiving TCD versus none in the PD cohort.
There were no significant differences in other clinical outcomes. The
cumulative incidence of acute grades II-IV GVHD, III-IV GVHD,
chronic-limited GVHD and chronic-extensive GVHDwere 50% vs
46%, 13% vs 18%, 39% vs 12% and 26% vs 33% respectively, in PD
vs TCD cohorts. With a median follow up of 2.8 years, Kaplan-Me-
ier estimates of overall survival, relapse and nonrelapse mortality
were 44%, 28% and 46% respectively for PD and 49%, 25% and
35% for TCD.
Conclusions: This comparison shows that the addition of 5x106/kg
photodepleted donor lymphocytes at day 0 to a CD34+ selected pe-
ripheral stem cell graft results in superior engraftment, equivalent
low rates of GVHD and equivalent disease control in HLA-matched
sibling transplantation.152
GRANULOCYTE TRANSFUSIONS IN A PATIENT WITH APLASTIC ANEMIA
SUFFERING FROM LIFE-THREATENING FUNGAL INFECTION – GAPPING
FOR HEMATOPOIETIC CELL TRANSPLANTATION
Bitan, M., Levin, D., Dvir, R., Sayar, D., Manistersky, M., Achituv, S.,
Rosenfeld-Kedar, H., Elhasid, R. Tel-Aviv Sourasky Medical Center, Te-
l-Aviv, Israel
Background: Acquired aplastic anemia (AA) is the most common
form of bone marrow failure. It is a life-threatening condition ac-
companied by severe infections, including several fungal specious.
Among these, fusarium is emerging pathogen in immunocomprom-
ized patients, particularly those with severe and prolonged neutrope-
nia. Allogeneic hematopoietic cell transplantation (HCT) is the
treatment of choice for AA in patients with matched sibling donor.Patient andMethods:One year old child was diagnosed as suffering
from acquired AA. Due to lack of matched related donor, he received
treatment with cyclosporine-A and anti-thymocytic globulin (ATG).
While being neutropenic, he developed disseminated life-threaten-
ing fusarium fungal infection including positive blood culture, mul-
tiple skin lesions and osteomyelitis. The patient received
amphotericin-B with no clinical improvement and general deteriora-
tion. In order to save the patient’s life and prepare him for future
transplant, he received 12 granulocyte transfusions over a period of
3 months. Granulocytes were harvested from adult volunteers using
granulocyte-colony-stimulating-factor (G-CSF) and dexametha-
sone. Every harvest was divided into 2 doses given every 12 hours.
Results: Skin lesions disappeared, blood cultures became negative
and osteomyelitis resolved during granulocyte transfusions. By that
time a new sibling was born, from whom cord blood was harvested
and HLA examination revealed matched sibling donor. Since the fu-
sarium disseminated infection was controlled the patient was able to
undergo allogeneic HCT using ATG (Fresenius, 5mg/kg/day for 5
days) and cyclophosphamide (50mg/kg/day for 4 days) as condition-
ing regimen. Neutrophil engraftment occurred on day +14 with do-
nor chimerism between 80-90%. No veno-oclusive-disease (VOD)
or graft-versus-host-disease (GVHD) was demonstrated. He is cur-
rently 140 days post transplant alive andwell with no evidence for the
fusarium infection.
Conclusions: Granulocyte transfusions by G-CSF-stimulated do-
nors while waiting HCT should be considered in patients suffering
from life-threatening fungal infections.153
Stemex® IS EXPANDING: PIVOTAL TRIAL NEARS COMPLETION, AND
DEVELOPMENT OF A CRYOPRESERVED PRODUCT IS UNDERWAY
Snyder, D., Landau, E., Rosenheimer, N.G., Mandel, J., Glukhman, E.,
Hasson, N., Lador, C., Olesinski, E., Hagler-Price, G., Leshem, A.,
Freind, E., Ben Abu, K., Sharabi, S., Shachaf, O., Israeli, H.,
Harati, D., Srur-Kidron, O., Galamidi Cohen, E., Peled, T. Gamida
Cell Ltd., Jerusalem, Israel
Cord blood transplantation (CBT) is limited by low number of
TNC and CD34+ cells, influencing the incidence and rate of hema-
topoietic recovery and risk of early transplant-related mortality. Ex
vivo expansion is a strategy to increase the number of progenitor cells
and improve clinical outcomes. Several early stage studies are evalu-
ating the clinical benefit of expansion, mainly in a double CBT con-
figuration. The StemEx trial evaluates the potential contribution
of expansion in a single CBT configuration. StemEx is manufactured
from a portion of a single CBU, originally frozen in 2 separate frac-
tions. CD133+ progenitor cells, purified from the smaller or equal
fraction, are cultured for 21-23 days with cytokines and a copper che-
lator, TEPA, which delays differentiation and promotes expansion of
progenitor cells with engraftment capabilities. A global pivotal reg-
istration study evaluating the safety and efficacy of StemEx in pa-
tients with hematological malignancies following myeloablative
treatment is currently completing recruitment. Safety and efficacy
outcomes of the study will be available in 2012. To date, 82 of 88 Ste-
mEx batches manufactured in 3 centralized GMP facilities, have
been successfully expanded: median fold expansion of TNC,
CD34+ cells and CFU over culture input were 399 (range 52-764),
75 (6-280) and 107 (43-662), respectively. Expansion of only a por-
tion of the CBU resulted in a median 8.4 fold increase (0.8-90.3)
in the number of CD34+ cells infused over the number that would
be infused from the entire CBUwithout expansion. TheCFUpoten-
tial of culture seeded CD133+ cells measured at day-0 of production
indicates the expansion potential of the cryopreserved CB cells. In all
six batches which failed to expand, day-0 CFU was low, while day-
0 CFU of all successfully expanded batches was within specification
ranges. This information, available before patient myeloablation,
strengthens the clinical applicability of StemEx. All StemEx batches
were successfully delivered and infused. We are currently in the last
stages of development of a frozen StemEx product. The added flex-
ibility in the timing of transplantation allows for changes resulting
from patient disease progression or complications. With the chal-
lenges of an ex vivo expanded product being successfully met in
the current registration trial, and the development of a frozen
